This report summarises the information from the surveillance systems which are used to monitor the Coronavirus Disease 2019 (COVID-19) pandemic in England. More information on the surveillance systems are available [here](#).

The report is based on week 26 (data between 22 June and 28 June 2020) and where available daily data up to 30 June 2020. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name.

**Summary**

COVID-19 activity continued to decline in England across a range of surveillance indicators during week 26 with just over 4,100 cases detected, compared to close to 5,800 in week 25. Over 75% of cases are now detected through testing outside of hospitals. Case detections are highest in the East Midlands, Yorkshire and Humber and North West. The increase in detections in Yorkshire and Humber in weeks 24 and 25 has reversed in week 26. At a local authority level, activity remains highest in Leicester, though the weekly incidence of confirmed cases has stabilised since week 25. Case detections are highest in adults aged 75 and older and in 15-44 year olds. There has been a small increase in positivity among 0-4 year olds through Pillar 1 (NHS and PHE) testing.

The overall number of acute respiratory infection incidents reported to PHE Health Protection Teams has declined in week 26. There have been declines in the number of care home and hospital incidents, the number of incidents in educational settings remains relatively stable whereas the number of incidents in workplaces has increased from 22 in week 25 to 43 in week 26. Since Pillar 2 testing became open to everyone during week 21 more outbreaks of mild disease have been detected in settings with healthy younger populations.

Community and syndromic surveillance indicators, while not specific for COVID-19, tend to be early indicators of changes in respiratory viral activity. These indicators have remained stable in week 26.

Positivity through GP sentinel swabbing among cases with symptom onset in week 25 was 3.1%. There have been no detections in cases with onset during week 26, though the number tested is low. There has been a decline in testing through the GP sentinel scheme which is likely due to increased access to testing through other routes.

Emergency department attendances with a COVID-19-like diagnosis and hospitalisations and critical care admissions for confirmed COVID-19 continue to decline slowly. Though there was a small increase in hospitalisations in the Midlands.

COVID-19 deaths also continue to decline and, while delays to death registrations can impact on the most recent data, there was no detectable excess mortality in week 25 in any age group or region.

Data based on samples from blood donors suggests that seroprevalence is plateauing. Seroprevalence remains highest in London, with an adjusted prevalence of around 13% based on samples from week 26. New data from the South West suggests that seroprevalence has plateaued at 3-4%. Seroprevalence remains highest in younger adults, though there have increases in prevalence in older adults over time, suggesting these age groups being affected later. These patterns may reflect differences in behaviour and mixing patterns in the different age groups.
As of 09:00 on 30 June 2020, a total of 1,500,996 people have been tested under Pillar 1. A total of 242,764 have been confirmed positive for COVID-19 in England under Pillar 1 and 2.

Figures 1 to 4, 6 and 8 to 11 and Tables 1 and 2 reflect cases tested under Pillar 1 (primarily in hospital testing of patients and some healthcare workers) and Pillar 2 (out of hospital testing). Figures 5 and 7 reflect cases tested under Pillar 1 only.

Overall case numbers and positivity continue to decrease in week 25. The highest number of cases continued to be seen in the older age groups, in particular in the 85+ age group. Rates and positivity of cases continue to be highest in the North and Central regions of England.

Figure 1: Laboratory confirmed COVID-19 cases tested under Pillar 1 (n=160,587) and Pillar 2 (n=82,177), based on sample week with overall positivity for Pillar 1 only (%)

* For the most recent week, more samples are expected therefore the decrease seen in this graph should be interpreted with caution. The data are shown by the week the specimen was taken from the person being tested. This gives the most accurate analysis of this time progression, but it does mean that the latest days’ figures may be incomplete.
Age and gender

Figure 2: Age/sex pyramids for laboratory confirmed COVID-19 cases tested through (a) Pillar 1 (n=158,228) and (b) Pillar 2 (n=81,267)

(a) Pillar 1
(b) Pillar 2

Figure 3: Weekly laboratory confirmed COVID-19 case rates per 100,000, tested under (a) Pillar 1 and (b) Pillar 2, by gender

(a) Pillar 1
(b) Pillar 2

Figure 4: Weekly laboratory confirmed COVID-19 case rates per 100,000, tested under (a) Pillar 1 and (b) Pillar 2, by age group

(a) Pillar 1
(b) Pillar 2
Figure 5: Weekly positivity (%) of laboratory confirmed COVID-19 cases tested under Pillar 1, (a) overall and by gender and (b) by male and age group (c) by female and age group (SGSS and Respiratory DataMart)

(a) Overall positivity % and by gender

(b) Male

(c) Female
Table 1: Cumulative number of cases under Pillar 1 (n=153,995) and Pillar 2 (n=80,611) and total number of people tested under Pillar 1 (n=1,358,539) by PHE Centres

<table>
<thead>
<tr>
<th>PHE Centres</th>
<th>Pillar 1 cases</th>
<th>Pillar 2 cases</th>
<th>Total number of people tested (under Pillar 1 only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>North East</td>
<td>10,558</td>
<td>4,470</td>
<td>73,320</td>
</tr>
<tr>
<td>North West</td>
<td>27,303</td>
<td>14,880</td>
<td>187,265</td>
</tr>
<tr>
<td>Yorkshire &amp; Humber</td>
<td>15,346</td>
<td>13,291</td>
<td>142,283</td>
</tr>
<tr>
<td>West Midlands</td>
<td>17,077</td>
<td>8,055</td>
<td>148,134</td>
</tr>
<tr>
<td>East Midlands</td>
<td>9,944</td>
<td>10,662</td>
<td>96,132</td>
</tr>
<tr>
<td>East of England</td>
<td>15,808</td>
<td>8,196</td>
<td>150,746</td>
</tr>
<tr>
<td>London</td>
<td>27,670</td>
<td>5,983</td>
<td>204,912</td>
</tr>
<tr>
<td>South East</td>
<td>22,332</td>
<td>10,351</td>
<td>213,939</td>
</tr>
<tr>
<td>South West</td>
<td>7,959</td>
<td>4,723</td>
<td>141,808</td>
</tr>
</tbody>
</table>

Figure 6: Weekly laboratory confirmed COVID-19 case rates per 100,000 population tested under (a) Pillar 1 and (b) Pillar 2, by PHE Centres and sample week

Figure 7: Weekly positivity of laboratory confirmed COVID-19 cases tested under Pillar 1 (%) by PHE Centres and sample week, (SGSS and Respiratory DataMart)
Figure 8: Cumulative rate of COVID-19 cases per 100,000 population tested under Pillar 1 and 2, by upper-tier local authority, England (box shows enlarged maps of London area)

Figure 9: Weekly rate of COVID-19 cases per 100,000 population tested under Pillar 1 and 2, by upper-tier local authority, England (box shows enlarged maps of London area)
Figure 10: Top 10 UTLA with the highest weekly rate of COVID-19 cases per 100,000 population tested under Pillar 1 and 2
**Ethnicity**

Figure 11: Ethnic group of cumulative laboratory confirmed COVID-19 cases tested under Pillar 1 and 2 (n=201,345)

- White
- Asian / Asian British
- Black / African / Caribbean / Black British
- Mixed / Multiple ethnic groups
- Other ethnic group

Table 2: Number of cases tested under Pillar 1 and 2, and percentage (%) by ethnic group and week

<table>
<thead>
<tr>
<th>Ethnic group</th>
<th>Week - number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>23</td>
</tr>
<tr>
<td>White</td>
<td>4,212 (78.0)</td>
</tr>
<tr>
<td>Asian / Asian British</td>
<td>817 (15.1)</td>
</tr>
<tr>
<td>Black / African / Caribbean / Black British</td>
<td>158 (2.9)</td>
</tr>
<tr>
<td>Mixed / Multiple ethnic groups</td>
<td>79 (1.5)</td>
</tr>
<tr>
<td>Other ethnic group</td>
<td>136 (2.5)</td>
</tr>
</tbody>
</table>
This section summarises the monitoring of acute respiratory infection incidents and internet based surveillance systems for COVID-19.

**Acute respiratory infection incidents, England**

Information on acute respiratory infection (ARI) incidents is based on situations reported to PHE Health Protection Teams (HPTs). These include:

- confirmed outbreaks of acute respiratory infections i.e. two or more laboratory confirmed cases (COVID-19, influenza or other respiratory pathogen) linked to a particular setting
- situations where an outbreak is suspected. All suspected outbreaks are further investigated by the HPT in liaison with local partners and a significant proportion do not meet the criteria of a confirmed outbreak. For example if suspected cases test negative for COVID-19 or other respiratory pathogens, or cases are subsequently found not to have direct links to the setting. Since Pillar 2 testing became open to everyone during week 21 more incidents of mild disease have been detected in settings with healthy young populations.

The number of incidents in each setting with at least one laboratory confirmed case of COVID-19 are reported below.

171 new ARI incidents have been reported in week 26 (Figure 12):

- 58 incidents were from care homes where 40 had at least one linked case that tested positive for SARS-CoV-2
- 13 incidents were from hospitals where 7 had at least one linked case that tested positive for SARS-CoV-2
- 40 incidents were from educational settings where 18 had at least one linked case that tested positive for SARS-CoV-2
- 4 incidents were from prisons where 2 had at least one linked case that tested positive for SARS-CoV-2
- 43 incidents were from workplace settings where 36 had at least one linked case that tested positive for SARS-CoV-2
- 13 incidents were from the other settings category where 6 had at least one linked case

![Figure 12: Number of acute respiratory outbreaks by institution, England](image-url)
### Acute respiratory infection incidents, England

**Table 3:** Total number of situations/incidents by institution and PHEC over the past four weeks with the total number in the last week in brackets

<table>
<thead>
<tr>
<th>PHE Centres</th>
<th>Care home</th>
<th>Hospital</th>
<th>Educational settings</th>
<th>Prisons</th>
<th>Workplace settings</th>
<th>Other settings</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>East of England</td>
<td>71(11)</td>
<td>9(3)</td>
<td>18(5)</td>
<td>1(0)</td>
<td>14(4)</td>
<td>4(0)</td>
<td>117(23)</td>
</tr>
<tr>
<td>East Midlands</td>
<td>16(0)</td>
<td>8(1)</td>
<td>9(1)</td>
<td>1(1)</td>
<td>25(12)</td>
<td>6(0)</td>
<td>65(15)</td>
</tr>
<tr>
<td>London</td>
<td>43(3)</td>
<td>15(3)</td>
<td>4(0)</td>
<td>4(3)</td>
<td>18(2)</td>
<td>38(12)</td>
<td></td>
</tr>
<tr>
<td>North East</td>
<td>23(4)</td>
<td>5(1)</td>
<td>7(1)</td>
<td>1(0)</td>
<td>5(4)</td>
<td>2(1)</td>
<td>43(11)</td>
</tr>
<tr>
<td>North West</td>
<td>55(14)</td>
<td>37(2)</td>
<td>9(4)</td>
<td>1(0)</td>
<td>7(0)</td>
<td>12(5)</td>
<td>121(25)</td>
</tr>
<tr>
<td>South East</td>
<td>71(8)</td>
<td>22(3)</td>
<td>30(7)</td>
<td>4(2)</td>
<td>7(3)</td>
<td>15(3)</td>
<td>149(26)</td>
</tr>
<tr>
<td>South West</td>
<td>24(2)</td>
<td>4(0)</td>
<td>25(7)</td>
<td>0(0)</td>
<td>2(1)</td>
<td>3(1)</td>
<td>61(11)</td>
</tr>
<tr>
<td>West Midlands</td>
<td>23(4)</td>
<td>11(2)</td>
<td>11(3)</td>
<td>0(0)</td>
<td>10(6)</td>
<td>5(0)</td>
<td>50(18)</td>
</tr>
<tr>
<td>Yorkshire and Humber</td>
<td>32(12)</td>
<td>5(0)</td>
<td>13(7)</td>
<td>1(1)</td>
<td>19(8)</td>
<td>16(4)</td>
<td>106(32)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>378(58)</td>
<td>107(13)</td>
<td>137(40)</td>
<td>9(4)</td>
<td>93(40)</td>
<td>83(16)</td>
<td>807(171)</td>
</tr>
</tbody>
</table>
NHS 111

The NHS 111 service monitors daily trends in phone calls made to the service in England, to capture trends in infectious diseases such as influenza and norovirus.

Up to 28 June 2020, the daily percentage of NHS 111 ‘potential COVID-19-like’ calls (as a percentage of total NHS 111 calls) remained stable (Figure 13). The daily number of NHS 111 ‘potential COVID-19’ completed online assessments decreased slightly (Figure 14).

Please note that NHS 111 callers (from 11 May) and NHS 111 online users (from 11 June 2020), who are assessed as having probable COVID-19 symptoms are now triaged using symptom specific pathways e.g. cold/flu, which are included in routine syndromic indicators.

Further information about these caveats is available from the PHE Remote Health Advice Syndromic Surveillance bulletin.

Figure 13 (a-b): NHS 111 telephony indicators (and 7-day moving average), England

(a) Daily potential COVID-19 calls as a percentage of total calls, all ages

(b) Daily cold/flu calls as a percentage of total calls, all ages

Figure 14 (a-b): NHS 111 completed online assessments (and 7-day moving average), England

(a) Daily ‘potential COVID-19’ online assessments as the number of completed online assessments, all ages

(b) Daily cold/flu online assessments as the number of completed online assessments, all ages
Community surveillance

Year: 2020     Week: 27

Internet based surveillance

PHE’s internet based surveillance systems aim to monitor the volume of people searching for typical symptoms of COVID-19 on the internet as well as tracking self-reported respiratory symptoms and health seeking behaviour patterns related to COVID-19.

Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API [1]. This model focuses on search queries about COVID-19 symptoms as well as generic queries about “coronavirus” (e.g. “covid-19”). The search query frequency time series has been weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data.

The overall and media-debiasing weighted scores decreased during week 26 (Figure 15).


Figure 15: Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England
Internet based surveillance

FluSurvey

An internet based surveillance system has been developed based on FluSurvey. FluSurvey is a web tool survey designed to monitor trends of influenza like illness (ILI) in the community using self-reported respiratory symptoms from registered participants. The platform has been adapted to capture respiratory symptoms, exposure risk and healthcare seeking behaviours among registered participants to contribute to national surveillance of COVID-19 activity.

A total of 3,715 participants completed the weekly COVID-19 surveillance survey in week 26, of which 80 (2.2%) reported fever or cough, a slight decrease to 2.9% reported in week 25. Although the most commonly reported method of access to healthcare services remains through telephone services, there has been an increase in visits to GP/hospitals (Figure 16).

Figure 16: Rate of contact with different healthcare services among FluSurvey participants reporting fever or cough symptoms, week 09 to 26, England
GP In Hours (GPIH) and GP Out of Hours (GPOOH), Syndromic surveillance

The **GP In Hours (GPIH) syndromic surveillance system** monitors the number of GP visits during regular hours of known clinical indicators. The **GP Out of Hours (GPOOH) syndromic surveillance system** monitors the numbers of daily unscheduled visits and calls to GPs during evenings, overnight, on weekends and on public holidays. Both systems cover around 55% of England’s population.

Up to 28 June 2020, GPIH consultations for potential COVID-19-like and ILI consultations remained stable (Figure 17). Through GPOOH consultations (up to 28 June 2020), the daily percentage (as a percentage of total contacts with a Read code) for ILI contacts remained stable and decreased in difficulty breathing/wheeze/asthma contacts following the increase observed in week 25 (Figure 18).

Please note GP data should be interpreted with caution due to changes in advice regarding accessing GP surgeries due to COVID-19. Further information about these caveats is available from the PHE GP In Hours Syndromic Surveillance bulletin.

**Figure 17 (a-b): GPIH clinical indicators, England**

(a) potential COVID-19 GP consultations, daily incidence rates per 100,000 population, all ages

(b) Influenza-like illness consultations, daily incidence rates per 100,000 population, all ages

**Figure 18 (a-b): GPOOH contacts indicators, England**

(a) Difficulty breathing/wheeze/asthma, daily contacts (%), all ages

(b) Influenza-like illness, daily contacts (%), all ages
**RCGP Swabbing Scheme**

This is an extended primary care surveillance system through the RCGP sentinel integrated clinical and virological scheme. The extension of the scheme was initiated on 24 February 2020. A sample of patients presenting to around 300 GP practices with Influenza-like Illness (ILI) and Lower Respiratory Tract Infections (LRTI) (not suspected for COVID-19) will be tested. This enables the week on week monitoring of test “positivity rate” to observe the trend in the proportion of people with confirmed COVID-19.

Up to 30 June 2020, a total of 4,815 patients have been tested of which 607 have tested positive for SARS-CoV-2 through this scheme. The overall positivity decreased at 0.0% (0/28) in week 26 compared to 3.1% (3/94) in the previous week (Figure 19). Consultations for ILI and LRTI continued to decrease (Figure 19).

**Figure 19: Overall weekly positivity (%), ILI and LRTI consultations rates (per 100,000), RCGP, England**

*For the most recent week, more samples are expected to be tested therefore the graph in Figures 17-19 should be interpreted with caution

*Positivity (%) is not calculated when the total number tested is less than 10
RCGP Swabbing Scheme

Figure 20: Overall positivity (%) (weekly) by PHE Region, England (RCGP)

Figure 21: Positivity (%) (weekly) by (a) age group and (b) gender, England (RCGP)

*For the most recent week, more samples are expected to be tested therefore the graph in Figures 17-19 should be interpreted with caution

*Positivity (%) is not calculated when the total number tested is less than 10
Emergency Department attendances, Syndromic surveillance


Up to 28 June 2020, the daily number of ED attendances for all ages as reported by 73 EDs in England during week 26, for COVID-19-like attendances remained stable (Figure 22).

Please note: the COVID-19-like ED indicator is an underestimation of the number of COVID-19 attendances as it only includes attendances with a COVID-19-like diagnosis as their primary diagnosis. The EDSSS COVID-19-like indicator should therefore be used to monitor trends in ED attendances and not to estimate actual numbers of COVID-19 ED attendances. Further information about these caveats is available from the [PHE Emergency Department Syndromic Surveillance](https://www.gov.uk/government/collections/edsss-bulletin) bulletin.

**Figure 22: COVID-19-like, daily ED attendances, all ages, England**
COVID-19 Hospitalisation in England Surveillance System (CHESS)

The CHESS surveillance system monitors daily new acute respiratory infections (ARI) and new laboratory confirmed COVID-19 admissions to hospital including critical care (ICU/HDU). Trends in hospital and critical care admission rates need to be interpreted in the context of testing recommendations.

A total of 134 NHS Trusts are now participating, although the number of Trusts reporting varies by day. The weekly rate of new admissions of COVID-19 cases is based on the trust catchment population of those NHS Trusts who made a new return. This may differ from other published figures such as the total number of people currently in hospital with COVID-19.

In week 26, the weekly admission rates for both hospitalisations and ICU/HDU COVID-19 admissions remained stable. The hospitalisation rate was at 2.18 per 100,000 in week 26 compared to 2.29 per 100,000 in the previous week. The ICU/HDU rate was at 0.19 per 100,000 in week 26 compared to 0.21 per 100,000 in the previous week (Figure 23). By NHS regions, the highest hospitalisation rate continues to be observed in the North West and the highest ICU/HDU rate was observed in the North East (Figure 24). By age group, the highest hospitalisation rate was seen in the 85+ year olds and the highest ICU/HDU rate was observed in the 65-74 year olds (Figure 25).

Figure 23: Weekly overall hospital and ICU/HDU admission rates per 100,000 of new COVID-19 positive cases reported through CHESS, England

![Admission rates graph](image-url)
COVID-19 Hospitalisation in England Surveillance System (CHESS)

Figure 24: Weekly admission rate for (a) hospital admissions and (b) ICU/HDU admissions by NHS regions of new COVID-19 positive cases reported through CHESS

Figure 25: Weekly admission rate for (a) hospital admissions and (b) ICU/HDU admissions by NHS regions of new COVID-19 positive cases reported through CHESS
COVID-19 Hospitalisation in England Surveillance System (CHESS)

Figure 26 and 27 are based on individual patient level data which are provided to CHESS from a subset of NHS Acute Trusts, therefore the data should be interpreted with caution as the distribution of age, sex and ethnic group may not be representative of all hospitalised patients.

Figure 26: Age/sex pyramid of new (a) hospital (lower level of care) (n=9,464) and (b) ICU/HDU (n=4,597) COVID-19 cases reported through CHESS, England

(a)

(b)
COVID-19 Hospitalisation in England Surveillance System (CHESS)

Figure 27: Ethnic group of new hospitalisations (lower level of care) (n=8,609) and ICU/HDU (n=3,892) COVID-19 cases reported through CHESS, England

<table>
<thead>
<tr>
<th>Ethnic Group</th>
<th>Hospitalisations</th>
<th>ICU/HDU</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>62.0%</td>
<td>88.8%</td>
</tr>
<tr>
<td>Asian / Asian British</td>
<td>6.5%</td>
<td>18.1%</td>
</tr>
<tr>
<td>Black / African / Caribbean / Black British</td>
<td>2.3%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Mixed / Multiple ethnic groups</td>
<td>0.8%</td>
<td>3.0%</td>
</tr>
<tr>
<td>Other ethnic group</td>
<td>1.7%</td>
<td>8.4%</td>
</tr>
</tbody>
</table>

proportion of admitted cases (%)

UK Severe Respiratory Failure (SRF) centres admissions

Between 03 March and 29 June 2020, a total of 216 laboratory confirmed COVID-19 admissions have been reported from the 5 SRFs in England. There were no laboratory confirmed COVID-19 admissions reported in week 26 compared to 1 admission reported in week 25 (Figure 28).

Figure 28: Laboratory confirmed ECMO admissions (COVID-19 and non-COVID-19 confirmed) to SRFs, England
Cumulative deaths

As of 5pm on 29 June 2020, a total of 39,187 cases under Pillar 1 and 2 with confirmed COVID-19 have died in England.

Figure 29: Cumulative number of deaths by week of death and age group, England (n=39,187)

* For the most recent week, more deaths will be reported therefore the decrease seen in this graph should be interpreted with caution

Table 4: Cumulative number of deaths (Pillar 1 and 2) by PHE Centres (n=38,847)

<table>
<thead>
<tr>
<th>PHE Centres</th>
<th>Number of deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>North East</td>
<td>2,319</td>
</tr>
<tr>
<td>North West</td>
<td>6,466</td>
</tr>
<tr>
<td>Yorkshire &amp; Humber</td>
<td>3,762</td>
</tr>
<tr>
<td>West Midlands</td>
<td>4,932</td>
</tr>
<tr>
<td>East Midlands</td>
<td>3,088</td>
</tr>
<tr>
<td>East of England</td>
<td>4,448</td>
</tr>
<tr>
<td>London</td>
<td>6,853</td>
</tr>
<tr>
<td>South East</td>
<td>5,148</td>
</tr>
<tr>
<td>South West</td>
<td>2,031</td>
</tr>
</tbody>
</table>
Cumulative deaths

Figure 30: Age/sex pyramid of laboratory confirmed COVID-19 (Pillar 1 and 2) deaths (n=39,187)

Figure 31: Ethnic group of confirmed COVID-19 (Pillar 1 and 2) deaths, England (n= 38,890)
Daily excess all-cause mortality, UK

Deaths occurring from 01 January to 24 June 2020 were assessed to calculate the daily excess above a baseline using age-group and region specific all cause deaths as provided daily by the General Register Office (GRO). The deaths were corrected to allow for delay to registration based on past data on these delays and the baseline was from the same day of the year in the previous 5 years +/- 7 days with an extrapolated time trend, and with 2 and 3 standard deviation (SD) limits shown (Figure 32).

Weeks in which at least 2 days exceeded the 3SD threshold are shown in Table 4 and the daily difference from the baseline by age and region is given in Figure 31. Note that as these data are by date of death with delay corrections, numbers are subject to change each week, particularly for more recent days.

No significant excess all-cause mortality was observed in week 25 overall, by age group or sub-nationally (Figure 32, 33 and Table 5).

Weekly all-cause mortality surveillance is monitored and reports can be found here.

Figure 32: Daily excess all-cause deaths in all ages, England, 01 January 2020 to 24 June 2020

^ based on same day in previous 5 years +/- 1 week with a linear trend projected
* corrected for delay to registration from death
Daily excess all-cause mortality, UK

Table 5: Excess all-cause deaths by (a) age group and (b) PHE centres, England

(a) Excess all-cause deaths by age group

<table>
<thead>
<tr>
<th>Age group</th>
<th>Excess detected in week 25 2020?</th>
<th>Weeks in excess since week 10 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>x</td>
<td>13 to 21, 23</td>
</tr>
<tr>
<td>under25</td>
<td>x</td>
<td>None</td>
</tr>
<tr>
<td>25to45</td>
<td>x</td>
<td>13 to 17</td>
</tr>
<tr>
<td>45to65</td>
<td>x</td>
<td>12 to 19</td>
</tr>
<tr>
<td>65to74</td>
<td>x</td>
<td>12 to 19</td>
</tr>
<tr>
<td>75to84</td>
<td>x</td>
<td>13 to 22</td>
</tr>
<tr>
<td>85+</td>
<td>x</td>
<td>13 to 21</td>
</tr>
</tbody>
</table>

(b) Excess all-cause deaths by PHE centres

<table>
<thead>
<tr>
<th>PHE centres</th>
<th>Excess detected in week 25 2020?</th>
<th>Weeks in excess since week 10 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>East of England</td>
<td>x</td>
<td>14 to 19</td>
</tr>
<tr>
<td>East Midlands</td>
<td>x</td>
<td>13 to 19, 21</td>
</tr>
<tr>
<td>London</td>
<td>x</td>
<td>12 to 19</td>
</tr>
<tr>
<td>North East</td>
<td>x</td>
<td>14 to 21</td>
</tr>
<tr>
<td>North West</td>
<td>x</td>
<td>13 to 20</td>
</tr>
<tr>
<td>South East</td>
<td>x</td>
<td>13 to 21</td>
</tr>
<tr>
<td>South West</td>
<td>x</td>
<td>13 to 19</td>
</tr>
<tr>
<td>West Midlands</td>
<td>x</td>
<td>13 to 21</td>
</tr>
<tr>
<td>Yorkshire and Humber</td>
<td>x</td>
<td>14 to 21, 23</td>
</tr>
</tbody>
</table>
Daily excess all-cause mortality, UK

Figure 33: Daily excess all-cause deaths by (a) age group and (b) PHE centres, England, 01 March 2020 to 24 June 2020

(a) Change from the 5 year baseline in number of deaths

(b) Change from the 5 year baseline in number of deaths
Sero-prevalence surveillance

Sero-prevalence epidemiology, England

Sero-epidemiological surveillance/studies enable the identification of the true number of infections within the general population and provides the ability to detect asymptomatic and mild infections. More information on this is available here.

In this week’s report updated results from the testing of samples provided by healthy blood donors aged 17-69 years, supplied by the NHS Blood and Transplant (NHS BT collection) are summarised. Donor samples from different geographic regions (approximately 1000 samples per region) in England are tested each week. The results presented here are based on testing using the Euroimmun assay for samples collected between weeks 13-26.

Overall population weighted prevalence among blood donors in England was 7.3% (95% CI 6.7% - 8%) (unadjusted) or 7.8% (95% CrI 9.1% - 8.6%) after adjustment for the accuracy of the Euroimmun assay (sensitivity and specificity) for the period 28 May – 22 June (weeks 22-26). This compares with 7.9% (95% CI 7.3% - 8.6%) (unadjusted) or 8.6% (95% CrI 7.8% - 9.4%) (adjusted) for the period of 30 April – 22 May (weeks 18-21).

Figure 34 shows the overall prevalence in each region over time which has been adjusted for the sensitivity and specificity of the Euroimmun assay. It is important to note that the sensitivity and specificity of assays are subject to change as further data becomes available.

Additional data from the sixth sampling in London and the third set of sampling from the South West regions are included in this week’s report (collected in week 25-26).

Adjusted prevalence estimates vary across the country and over time. In London where prevalence estimates are highest, overall adjusted prevalence increased from 1.5% (week 13) to 10.5% (weeks 15-16) to 14.5% (week 18) to 15.4% (week 21) remaining stable more recently at 14.9% (week 24) and 13.2% in the most recent data (week 26). Given that antibody response takes at least two weeks to become detectable, those displaying a positive result in week 18 are likely to have become infected before mid-April. The plateauing observed since week 18 demonstrates the impact of lock down measures on new infections and it is probably too soon to see any change in incidence related to relaxation of control measures.

The lower prevalence in samples from other regions including the South East, South West and North East regions is consistent with data from other surveillance systems. In the most recent data from weeks 25-26, adjusted prevalence amongst donors in the South West has plateaued at 3.7% (week 24) and 3.4% in week 26. Similar trends have been observed in other regions including the North East of England with adjusted prevalence at 6.3% in week 24 compared with 7.0% in week 20.

In some regions prevalence estimates are slightly lower in recent weeks. For example, the adjusted prevalence in the North West of England is slightly lower at 8.8% in week 23 compared with 10.6% in week 19. A more pronounced change was noted in the East of England with a lower adjusted prevalence of 4.2% (week 22) compared with 8.1% (week 19). This is likely driven by some changes in the precise locations of sampling over time with the most recent set of samples from both regions containing significantly fewer samples from higher prevalence areas e.g. in the most recent set from East of England, there were significantly less samples from areas of higher prevalence with a trend of increased prevalence with proximity to London observed.

Age specific prevalence estimates have changed over time with prevalence notably higher in the young adults when the increases were first observed in areas experiencing the outbreak earlier (Figure 35). Over time, although individuals aged 17-29 years continue to display the highest prevalence, there has been some evidence that prevalence in older adults has increased later in the epidemic. These patterns may reflect differences in behaviour and mixing patterns in the different age groups.
Sero-prevalence surveillance

Year: 2020     Week: 27

Sero-prevalence epidemiology, England

Figure 34: Overall SARS-CoV-2 antibody seroprevalence (%) in blood donors by PHE centres, using Euroimmun test adjusted for sensitivity (82.5%) and specificity (99.1%) and 95% confidence intervals (dashed lines)

Figure 35: SARS-CoV-2 antibody seroprevalence in blood donors by age group, using Euroimmun test adjusted for sensitivity (82.5%) and specificity (99.1%); error bars show 95% confidence intervals
Global situation

Globally, up to 30 June 2020, a total of 10,232,597 cases of COVID-19 infection have been reported worldwide, including 505,601 COVID-19 related deaths.

Figure 36: Global map of cumulative COVID-19 cases
Global situation

Figure 37: Global map of weekly COVID-19 case incidence rate per 100,000, week 26 2020

PHE has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002.